Tobira Therapeutics Inc. (NASDAQ:TBRA) saw unusually-strong trading volume on Monday . Approximately 2,280,128 shares traded hands during mid-day trading, an increase of 1,029% from the previous session’s volume of 201,936 shares.The stock last traded at $4.73 and had previously closed at $11.25.

A number of equities research analysts have issued reports on TBRA shares. Zacks Investment Research downgraded shares of Tobira Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, April 22nd. Cowen and Company reiterated a “buy” rating on shares of Tobira Therapeutics in a research report on Tuesday, May 10th. Cantor Fitzgerald started coverage on shares of Tobira Therapeutics in a research report on Wednesday, July 6th. They issued a “buy” rating and a $27.00 target price for the company. Leerink Swann reiterated a “buy” rating and issued a $18.00 target price on shares of Tobira Therapeutics in a research report on Tuesday, May 10th. Finally, HC Wainwright started coverage on shares of Tobira Therapeutics in a research report on Monday, April 11th. They issued a “buy” rating and a $22.00 target price for the company. Five equities research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and a consensus price target of $18.60.

The firm’s market cap is $84.67 million. The firm’s 50-day moving average price is $11.54 and its 200-day moving average price is $8.75.

Tobira Therapeutics (NASDAQ:TBRA) last announced its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by $0.12. Analysts forecast that Tobira Therapeutics Inc. will post ($2.49) earnings per share for the current fiscal year.

In other Tobira Therapeutics news, major shareholder A/S Novo sold 59,067 shares of the business’s stock in a transaction that occurred on Wednesday, July 13th. The stock was sold at an average price of $12.02, for a total value of $709,985.34. Following the completion of the sale, the insider now owns 1,914,541 shares in the company, valued at $23,012,782.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

An institutional investor recently bought a new position in Tobira Therapeutics stock. Marshall Wace LLP bought a new position in shares of Tobira Therapeutics Inc. (NASDAQ:TBRA) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 107,493 shares of the biopharmaceutical company’s stock, valued at approximately $1,080,000. Marshall Wace LLP owned about 0.57% of Tobira Therapeutics as of its most recent filing with the SEC.

Tobira Therapeutics, Inc, formerly Regado Biosciences, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company’s lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.